Clinical Trials Logo

Familial Hypercholesterolemia clinical trials

View clinical trials related to Familial Hypercholesterolemia.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT03331666 Terminated - Clinical trials for Familial Hypercholesterolemia

Impact of LDL-cholesterol Lowering on Platelet Activation

Start date: November 16, 2018
Phase: Phase 4
Study type: Interventional

The primary goal is to assess the impact of Evolocumab therapy on platelet function of familial hypercholesterolemia (FH) patients in a randomized, double blind study. Evolocumab is a humanized monoclonal antibody that targets circulating PCSK9, increases hepatic LDL receptor, decreases plasma LDL cholesterol and reduces risk of cardiovascular events. Evolocumab (brand name Rapatha) has been approved by FDA along with diet and maximally tolerated statin therapy in adults with FH or atherosclerotic heart or blood vessel problems, who need additional lowering of LDL cholesterol. The secondary goal is to determine if platelet activation or the response to Evolocumab therapy is modified by rs3184504 polymorphism. The investigators believe that these investigations will complement ongoing studies to demonstrate that Evolocumab reduces athero-thrombotic risk and aid the decision-making as to whether Evolocumab can reduce the atherothrombotic risk in acute coronary syndrome (ACS) patients.

NCT ID: NCT02013713 Terminated - Clinical trials for Familial Hypercholesterolemia

French Observatory of Familial Hypercholesterolemia in Cardiology

FH Care
Start date: November 2014
Phase:
Study type: Observational

The Family Hypercholesterolemia remains poorly diagnosed disease with an outlet sometimes suboptimal care. However, the Family Hypercholesterolemia exposes patients concerned at increased cardiovascular risk. The frequency of familial hypercholesterolemia in cardiologic is little studied and remains unknown, and there is little data on the profile of patients, diagnostic methods and management. Main objectives: - Establish a monitoring patients with hypercholesterolemia Family cardiology in France - Characterize the Family hypercholesterolemia in cardiology, including assessing the frequency of the most severe forms, which are at higher cardiovascular risk.

NCT ID: NCT00079859 Terminated - Clinical trials for Familial Hypercholesterolemia

Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy

Start date: October 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if implitapide, used in conjunction with other lipid-lowering therapies, is safe and effective when compared to placebo in lowering low-density lipoprotein cholesterol (LDL-C) in patients with heterozygous familial hypercholesterolemia (HeFH).

NCT ID: NCT00079846 Terminated - Clinical trials for Familial Hypercholesterolemia

Implitapide in Patients With Homozygous Familial Hypercholesterolemia (HoFH) on Maximal Concurrent Lipid-Lowering Therapy

Start date: September 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if implitapide, used in conjunction with other lipid-lowering therapies, is safe and effective when compared to placebo in lowering low-density lipoprotein cholesterol (LDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).